10-Q Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 Q3 2018

Filing Information

Form Type	10-Q
Accession Number	`0001564590-18-019930`
Period End Date	20180630
Filing Date	20180807
Fiscal Year	2018
Fiscal Period	Q3
XBRL Instance	arwr-20180630.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 74 Income Statement 56 Cash Flow Statement 60 Stockholders Equity 18

Balance Sheet 74 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Common stock, shares authorized	`CommonStockSharesAuthorized`	145.00M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$24.84M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	87.85M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$28.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$85.37M	USD	Point-in-time
Common stock, shares issued	`CommonStockSharesIssued`	74.79M	shares	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$38.38M	USD	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$67.80K	USD	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	74.79M	shares	Point-in-time
Common stock, shares outstanding	`CommonStockSharesOutstanding`	87.85M	shares	Point-in-time
Accounts receivable	`AccountsReceivableNetCurrent`	$14.97K	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$1.10M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$867.36K	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$1.36M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$279.05K	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$32.48M	USD	Point-in-time
Short term investments	`HeldToMaturitySecuritiesCurrent`	$40.77M	USD	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$67.90M	USD	Point-in-time
TOTAL CURRENT ASSETS	`AssetsCurrent`	$61.87M	USD	Point-in-time
Long term investments	`HeldToMaturitySecuritiesNoncurrent`	$17.67M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$15.51M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$14.03M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$20.46M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$19.19M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$141.92K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$141.92K	USD	Point-in-time
TOTAL ASSETS	`Assets`	$112.90M	USD	Point-in-time
TOTAL ASSETS	`Assets`	$104.02M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$4.08M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$2.17M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$2.16M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$4.56M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$1.15M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$3.40M	USD	Point-in-time
Deferred rent	`DeferredRentCreditCurrent`	$440.58K	USD	Point-in-time
Deferred rent	`DeferredRentCreditCurrent`	$440.58K	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$943.20K	USD	Point-in-time
Deferred revenue	`DeferredRevenueCurrent`	$5.27M	USD	Point-in-time
Derivative liabilities	`DerivativeLiabilitiesCurrent`	$695.11K	USD	Point-in-time
Note Payable	`NotesPayableCurrent`	$219.89K	USD	Point-in-time
Note Payable	`NotesPayableCurrent`	$208.51K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$46.41K	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$46.41K	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$7.13M	USD	Point-in-time
TOTAL CURRENT LIABILITIES	`LiabilitiesCurrent`	$18.70M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$1.66M	USD	Point-in-time
Deferred rent, net of current portion	`DeferredRentCreditNoncurrent`	$1.93M	USD	Point-in-time
Note Payable, net of current portion	`LongTermNotesPayable`	$2.16M	USD	Point-in-time
Note Payable, net of current portion	`LongTermNotesPayable`	$2.33M	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$200.00K	USD	Point-in-time
Other non-current liabilities	`OtherLiabilitiesNoncurrent`	$200.00K	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$4.45M	USD	Point-in-time
TOTAL LONG-TERM LIABILITIES	`LiabilitiesNoncurrent`	$4.02M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 87,854,651 and 74,785,426 shares issued and outstanding as of June 30, 2018 and September 30, 2017, respectively	`CommonStockValue`	$180.22K	USD	Point-in-time
Common stock, $0.001 par value; 145,000,000 shares authorized; 87,854,651 and 74,785,426 shares issued and outstanding as of June 30, 2018 and September 30, 2017, respectively	`CommonStockValue`	$167.16K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$514.04M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$578.64M	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.34K	USD	Point-in-time
Accumulated other comprehensive income (loss)	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$33.23K	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-476.50M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-432.82M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$81.42M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders' equity	`StockholdersEquity`	$102.31M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$-555.19K	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
TOTAL STOCKHOLDERS EQUITY	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$101.76M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$112.90M	USD	Point-in-time
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY	`LiabilitiesAndStockholdersEquity`	$104.02M	USD	Point-in-time

Income Statement 56 line items

Line Item	Tag	Value	Unit	Period
REVENUE	`Revenues`	$9.34M	USD	1 Quarter
REVENUE	`Revenues`	$4.89M	USD	3 Qtrs
REVENUE	`Revenues`	$727.38K	USD	1 Quarter
REVENUE	`Revenues`	$22.69M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$12.05M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$36.97M	USD	3 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$11.14M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$37.36M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$3.92M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$4.59M	USD	1 Quarter
General and administrative expenses	`GeneralAndAdministrativeExpense`	$12.08M	USD	3 Qtrs
General and administrative expenses	`GeneralAndAdministrativeExpense`	$12.68M	USD	3 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$49.65M	USD	3 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$16.65M	USD	1 Quarter
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$49.44M	USD	3 Qtrs
TOTAL OPERATING EXPENSES	`OperatingExpenses`	$15.06M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-15.92M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-5.71M	USD	1 Quarter
OPERATING LOSS	`OperatingIncomeLoss`	$-44.77M	USD	3 Qtrs
OPERATING LOSS	`OperatingIncomeLoss`	$-26.75M	USD	3 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$313.70K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$131.36K	USD	1 Quarter
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$645.78K	USD	3 Qtrs
Interest income (expense), net	`InterestIncomeExpenseNonoperatingNet`	$265.25K	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$432.14K	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$63.06K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$1.52M	USD	3 Qtrs
Other income (expense)	`OtherNonoperatingIncomeExpense`	$1.31M	USD	3 Qtrs
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$3.10M	USD	3 Qtrs
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$194.42K	USD	1 Quarter
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$1.08M	USD	3 Qtrs
TOTAL OTHER INCOME (EXPENSE)	`NonoperatingIncomeExpense`	$313.70K	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-23.65M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-43.69M	USD	3 Qtrs
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-5.52M	USD	1 Quarter
LOSS BEFORE INCOME TAXES	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-15.61M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-5.52M	USD	1 Quarter
NET LOSS	`ProfitLoss`	$-43.69M	USD	3 Qtrs
NET LOSS	`ProfitLoss`	$-23.65M	USD	3 Qtrs
NET LOSS	`ProfitLoss`	$-15.61M	USD	1 Quarter
NET LOSS PER SHARE - BASIC & DILUTED	`EarningsPerShareBasicAndDiluted`	$-0.53	USD	3 Qtrs
NET LOSS PER SHARE - BASIC & DILUTED	`EarningsPerShareBasicAndDiluted`	$-0.07	USD	1 Quarter
NET LOSS PER SHARE - BASIC & DILUTED	`EarningsPerShareBasicAndDiluted`	$-0.18	USD	1 Quarter
NET LOSS PER SHARE - BASIC & DILUTED	`EarningsPerShareBasicAndDiluted`	$-0.32	USD	3 Qtrs
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	74.77M	shares	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	73.60M	shares	3 Qtrs
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	87.63M	shares	1 Quarter
Weighted average shares outstanding - basic and diluted	`WeightedAverageNumberOfShareOutstandingBasicAndDiluted`	82.15M	shares	3 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-36.57K	USD	3 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$12.31K	USD	1 Quarter
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-25.84K	USD	3 Qtrs
Foreign Currency Translation Adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-28.60K	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-43.73M	USD	3 Qtrs
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-5.51M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-15.63M	USD	1 Quarter
COMPREHENSIVE LOSS	`ComprehensiveIncomeNetOfTax`	$-23.67M	USD	3 Qtrs

Cash Flow Statement 60 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-5.52M	USD	1 Quarter
Net loss	`ProfitLoss`	$-43.69M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-23.65M	USD	3 Qtrs
Net loss	`ProfitLoss`	$-15.61M	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$432.14K	USD	3 Qtrs
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$63.06K	USD	1 Quarter
Change in value of derivatives	`UnrealizedGainLossOnDerivatives`	$1.52M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$5.82M	USD	3 Qtrs
Stock-based compensation	`ShareBasedCompensation`	$5.88M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$3.54M	USD	3 Qtrs
Depreciation and amortization	`DepreciationAndAmortization`	$3.47M	USD	3 Qtrs
Amortization/(accretion) of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$140.04K	USD	3 Qtrs
Amortization/(accretion) of note premiums	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-582.37K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$862.31K	USD	3 Qtrs
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-52.82K	USD	3 Qtrs
Prepaid expenses and Other Current Assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-3.18M	USD	3 Qtrs
Prepaid expenses and Other Current Assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-856.25K	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$8.80M	USD	3 Qtrs
Deferred revenue	`IncreaseDecreaseInDeferredRevenue`	$-4.33M	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-4.35M	USD	3 Qtrs
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-1.91M	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-4.65M	USD	3 Qtrs
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-5.34M	USD	3 Qtrs
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$-264.92K	USD	3 Qtrs
Other	`IncreaseDecreaseInOtherOperatingLiabilities`	$-312.00K	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivities`	$-44.54M	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES	`NetCashProvidedByUsedInOperatingActivities`	$-14.74M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$7.81M	USD	3 Qtrs
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$711.78K	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$39.90M	USD	3 Qtrs
Purchases of marketable securities	`PaymentsToAcquireMarketableSecurities`	$47.17M	USD	3 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$3.29M	USD	3 Qtrs
Proceeds from sale of marketable securities	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$37.20M	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivities`	$-44.43M	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	`NetCashProvidedByUsedInInvestingActivities`	$-10.68M	USD	3 Qtrs
Principal payments on notes payable	`RepaymentsOfNotesPayable`	$97.14K	USD	3 Qtrs
Principal payments on notes payable	`RepaymentsOfNotesPayable`	$154.99K	USD	3 Qtrs
Payments of taxes for net share settled restricted stock unit issuances	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$54.67K	USD	3 Qtrs
Payments of taxes for net share settled restricted stock unit issuances	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$417.14K	USD	3 Qtrs
Proceeds from the exercises of warrants and stock options	`ProceedsFromExercisesOfWarrantsAndStockOptions`	$272.82K	USD	3 Qtrs
Proceeds from the exercises of warrants and stock options	`ProceedsFromExercisesOfWarrantsAndStockOptions`	$2.01M	USD	3 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$12.42M	USD	3 Qtrs
Proceeds from the issuance of common stock	`ProceedsFromIssuanceOfCommonStock`	$56.59M	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivities`	$12.18M	USD	3 Qtrs
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES	`NetCashProvidedByUsedInFinancingActivities`	$58.38M	USD	3 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$3.16M	USD	3 Qtrs
NET INCREASE (DECREASE) IN CASH	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-46.98M	USD	3 Qtrs
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$24.84M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$28.00M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$85.37M	USD	Point-in-time
CASH AT BEGINNING OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$38.38M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$24.84M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$28.00M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$85.37M	USD	Point-in-time
CASH AT END OF PERIOD	`CashAndCashEquivalentsAtCarryingValue`	$38.38M	USD	Point-in-time
Interest Paid	`InterestPaidNet`	$131.43K	USD	3 Qtrs
Interest Paid	`InterestPaidNet`	$142.03K	USD	3 Qtrs
Income Tax Credits Refunded	`ProceedsFromRefundableIncomeTaxCredits`	$3.64M	USD	3 Qtrs
Income Tax Paid	`IncomeTaxesPaid`	$2.40K	USD	3 Qtrs
Income Tax Paid	`IncomeTaxesPaid`	$2.40K	USD	3 Qtrs

Stockholders Equity 18 line items

Line Item	Tag	Value	Unit	Period
Stock issued, price per share	`SharesIssuedPricePerShare`	$5.25	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
Beginning Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$101.76M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$5.82M	USD	3 Qtrs
Exercise of stock options, Amount	`StockIssuedDuringPeriodValueStockOptionsExercised`	$1.03M	USD	3 Qtrs
Exercise of stock options, Shares	`StockIssuedDuringPeriodSharesStockOptionsExercised`	283,627.00	shares	3 Qtrs
Exercise of warrants, Amount	`StockIssuedDuringPeriodValueExerciseOfWarrants`	$1.24M	USD	3 Qtrs
Common stock- Restricted Stock Units vesting, Amount	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	$-54.67K	USD	3 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-36.57K	USD	3 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$12.31K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-25.84K	USD	3 Qtrs
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-28.60K	USD	1 Quarter
Net loss for the nine months ended June 30, 2018	`ProfitLoss`	$-5.52M	USD	1 Quarter
Net loss for the nine months ended June 30, 2018	`ProfitLoss`	$-43.69M	USD	3 Qtrs
Net loss for the nine months ended June 30, 2018	`ProfitLoss`	$-23.65M	USD	3 Qtrs
Net loss for the nine months ended June 30, 2018	`ProfitLoss`	$-15.61M	USD	1 Quarter
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$80.87M	USD	Point-in-time
Ending Balance, Amount	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$101.76M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.